The expected boost in the number studies revealing the capabilities of CRISPR/Cas9 for editing of TP53 gene with respect to the treatment of hereditary diseases might urge the need for clinical validation of germline genome editing on human embryos, a topic of hot debate. Here, TP53 is linked to hereditary disease.